Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyBorD Plus Daratumumab for MGRS
NCT06083922Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in monoclonal gammopathy of renal significance (MGRS), multiple myeloma (MM), myeloma cast nephropathy (LCCN), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
monoclonal gammopathy of renal significance (MGRS)multiple myeloma (MM)myeloma cast nephropathy (LCCN)
Beyond the preview
Go deeper on NCT06083922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083922.